UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack, Inc. (NASDAQ: GCTK) completed a strategic business combination with Lōkahi Therapeutics, creating a publicly listed platform for identifying and advancing healthcare assets. Lōkahi Therapeutics securityholders will hold approximately 90% of the combined company on a fully diluted basis. Erik Emerson was appointed CEO, while Glucotrack's continuous blood glucose monitoring (CBGM) technology will operate as a separate subsidiary under Paul Goode's leadership. The transaction is supported by a planned private placement financing.